Smad4 is a tumor suppressor gene that is commonly lost or mutated in colorectal and pancreatic cancers. The activated transforming growth factor-b (TGF-b) receptor phosphorylates Smad2 and Smad3, which then complex with Smad4 and translocate to the nucleus. Smad4 mutations when detected as present in some human cancers have been considered sufficient to inactivate TGF-b signaling. In this work, we describe a colon cancer cell line, VACO-9M, that is Smad4 null when analysed by multiple assays. To study the role of Smad4 in TGF-binduced translocation of the receptor-activated Smads to the nucleus, we analysed by immunofluorescence the cellular localization of endogenous Smad2 and Smad3 after TGF-b treatment of VACO-9M, plus four additional Smad4 null cell lines of breast (MDA-MB-468), or pancreatic (BxPC3, Hs766T, CFPAC-1) origin. In each cell line, TGF-b treatment resulted in both Smad2 and Smad3 moving to the nucleus in a Smad4-independent fashion. Nuclear translocation of Smad2 and Smad3 was, however, not sufficient to activate reporters for TGF-binduced transcriptional responses, which were however restored by transient transfection of wild-type Smad4. We conclude that Smad4 is not required for nuclear translocation of Smad2 and Smad3, but is needed activation of at least certain transcriptional responses.
Introduction
Transforming growth factor-beta (TGF-b) is member of a superfamily of cytokines that affect a variety of cell types and elicit a wide array of cell-type-specific biological effects such as differentiation, migration, cell cycle arrest, adhesion, extracellular matrix production, and apoptosis (Markowitz and Roberts, 1996; Massague´, 1998) . TGF-b-induced signaling occurs when the TGF-b ligand binds to the type II receptor (RII), which then heterodimerizes with the type I receptor (RI) and activates the RI kinase domain through phosphorylation of a domain called the 'GS region' (Wrana et al., 1992 (Wrana et al., , 1994 Franzen et al., 1993) . RI then phosphorylates a subgroup of Smad proteins, known as the receptor-activated Smads (R-Smads). For TGF-b signaling, RI phosphorylates R-Smads 2 and 3 at a Cterminal SSXS motif (Abdollah et al., 1997; Souchelnytshyi et al., 1997) , which then results in the release of Smad2 and/or Smad3 from the receptor complex. Smad2/3 then bind to Smad4 (also known as DPC4), and this complex translocates to the nucleus whereupon transcriptional activation of a variety of genes occurs Attisano and Wrana, 1998; Massague´and Wotton, 2000) .
Smad4 has been determined to be a tumor suppressor gene through demonstration of inactivation in several cancer types Riggins et al., 1996) . Smad4 is mutated in almost 50% of pancreatic cancers and approximately in 20% of colon cancers Riggins et al., 1996; Thiagalingam et al., 1996) . Because Smad4 serves as a common binding partner for all R-Smads, it is believed that Smad4 plays a central role in TGF-b signaling. One question that has been addressed is the role Smad4 plays in the movement of RSmads to the nucleus after TGF-b treatment. Initial studies by Liu et al. suggested that Smad2 and Smad3 could in SW480.7 cells translocate to the nucleus in the absence of Smad4 (Liu et al., 1997; Calonge and Massague´, 1999) . However, SW480.7 cells were subsequently shown to express a low-level Smad4 transcript (Calonge and Massague´, 1999) . Therefore, to readdress this question, we examined a set of colon cancer cell lines to identify one, VACO-9M, that assayed as completely Smad4 null. We have employed VACO-9M, plus several additional cell lines in which Smad4 is genetically inactivated, to re-examine the ability of Smad2 and Smad3 to translocate to the nucleus independent of Smad4. We find that TGF-b treatment of Smad4 null cells does induce nuclear accumulation of Smad2 and Smad3. Nuclear accumulation of Smad2 and Smad3, however, does not by itself trigger TGF-b transcriptional responses. Reconstitution of Smad4 in Smad4 null cells restores some, but not all, of the TGF-b effector activities.
Results

VACO-9M is Smad4 null
We first screened by RT-PCR a group of 22 colon cancer cell lines for expression of Smad4 transcript. One cell line, VACO-9M, did not demonstrate any detectable Smad4 transcript when assayed by RT-PCR (Figure 1a) . Lack of Smad4 expression was further confirmed by Northern blot using the full-length cDNA as a probe (data not shown). To ensure that the RNA sample from this cell line was not degraded, RT-PCR of full-length Smad2 (Figure 1b ) and Smad3 (data not shown) were also performed and this resulted in products of the correct size, which did not contain any mutations when sequenced (data not shown). Immunoblotting with a Smad4-specific monoclonal antibody for Smad4 using VACO-9M cell lysates resulted in no Smad4 protein being detected, as compared to the Smad4 expressing cell lines FET and V235 (Figure 2) . A similar lack of a Smad4 protein was also detected in the Smad4 null control cell lines BxPC3, MDA-MB-468 and HCT116 Smad4 knockout (Figure 2) , and Hs766T and CFPAC-1 (data not shown) Zhou et al, 1998; Dai et al., 1999) . While the VACO-9M Smad4 allele was detectable by Southern analyses, our aggregate data clearly demonstrate that VACO-9M is null for Smad4 expression.
Smad2 and SmadS translocation to the nucleus with TGF-b treatment in Smad4 null cell lines
To test the requirement for Smad4 in the TGF-binduced nuclear localization of R-Smads, we examined Smad2 and Smad3 responses to TGF-b by immunofluorescence staining in five confirmed Smad4 null cell lines. These included VACO-9M, as well as the breast cancer cell line MDA-MB-468, and the pancreatic cell lines BxPC3, Hs766T, and CFPAC-1. MDA-MB-468, BxPC3, Hs766T, and CFPAC-1 have all been analysed and demonstrated to be Smad4 null due to homozygous deletions of all or part of the Smad4 gene Dai et al., 1999) . Each of these Smad4 null lines has been shown to express both Smad2 and Smad3 (as well as TGF-b receptors RI and RII), and in each the loss of TGF-b sensitivity has been ascribed to the loss of Smad4 (SPF, SM, unpublished results; Lagna et al., 1996; Schutte et al., 1996; Grau et al., 1997; Dai et al., 1999; Giehl et al., 2000; Simeone et al., 2000; Venkatasubbarao et al., 2000) .
As an initial control to demonstrate that the lines used in these studies are Smad4 null, we first analysed each cell line for Smad4 by immunofluorescence staining using the anti-Smad4 specific antibody SC-7966 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). As expected, Smad4 was not detected in VACO-9M, MDA-MB-468, and BxPC3 after 2 h of 10 ng/ml TGFb treatment (Figure 3a , rows 1-3). The two other pancreatic cell lines, Hs766T and CFPAC-1, displayed similar results as BxPC3 (data not shown). As a positive control for Smad4 staining and translocation to the nucleus after TGF-b treatment, we employed the previously described VACO-400-RII cell line, constructed by stably transducing a wild-type RII gene into the parental RII mutant cell line VACO-400 (Grady et al., 1999) . Stable reconstitution of wild-type RII results in restoration of TGF-b sensitivity in VACO-400, as assayed by the TGF-b-responsive reporter plasmid, p3TP-Lux, and by the suppression of colonyforming activity (Grady et al., 1999) . In the absence . In all, 35 mg of protein from cell lysates was separated by SDS-PAGE and an anti-Smad4-specific monoclonal antibody was used for Western immunoblotting. Following the blot for Smad4, the same membrane was used to immunoblot for actin in order to verify equality in sample loading Smad4 independent Smad2 and Smad3 nuclear localization SP Fink et al of TGF-b treatment, VACO-400RII demonstrated a diffuse Smad4 staining pattern, with some nuclear staining; whereas, following TGF-b treatment of VACO-400-RII, the great majority of the Smad4 protein was clearly localized to the nucleus (Figure 3a , rows 4 and 5).
In this group of cell lines, we next employed the antiSmad2 antibody, S66220 (Transduction labs, Lexington, KY, USA) and the anti-Smad3 antibody, SC-8332 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to determine the cellular localization of endogenous Smad2 and Smad3 both in the absence of and following 2 h treatment with TGF-b. In the absence of TGF-b treatment, Smad2 and Smad3 showed a diffuse cytoplasmic staining pattern in VACO-9M, MDA-MB-468, BxPC3, and VACO-400RII, although in BxPC3 and VACO-400RII a few cells also exhibited nuclear staining (Figure 3b, c) . Diffuse cytoplasmic staining of Smad2 and Smad3 were also detected with Hs766T (data not shown). However, when each of these cell lines was incubated with 10 ng/ml of TGF-b for 2 h, strong nuclear localization of both Smad2 and Smad3 was clearly detected in a majority of cells for each cell line tested (Figure 3b, c) . In one Smad4 null cell line, CFPAC-1, Smad2, and Smad3 demonstrated more prominent nuclear staining in the absence of TGF-b, and perhaps because of this, further nuclear enhancement was somewhat less pronounced following the addition of TGF-b. However, the examples of VACO-9M, MDA-MB-468, and BxPC3 clearly suffice to demonstrate that Smad2 and Smad3 can translocate to the nucleus after TGF-b treatment in a rapid, Smad4-independent fashion.
Smad4 is required for TGF-b-induced transcriptional responses
TGF-b can clearly induce nuclear translocation of the Smad2 and Smad3 transcription factors in the Smad4 null VACO-9M cell line, suggesting that these transcription factors might even in the absence of Smad4 be able to mediate some TGF-b-induced transcriptional responses. To investigate this, we examined the responsiveness of VACO-9M cells to TGF-b induction of the p3TP-Lux reporter plasmid that contains TGF-b responsive elements from both the PAI-1 and collagenase promoters, and has been used extensively in the study of TGF-b responsiveness (Wrana et al., 1992) . Figure 4 demonstrates that VACO-9M cells that had been specifically assayed as Smad4 null indeed showed no induction of p3TP-Lux activity when treated with TGF-b, a finding consistent with previous studies using these cells (Fink et al., 2001) . However, transient transfection of Smad4 into TGF-b-treated VACO-9M cells increased p3TP-Lux activity 5.5-fold (Figure 4) . Thus, nuclear translocation of Smad2 and Smad3 are insufficient, and Smad4 is required for induction of the TGF-b-induced transcriptional responses assayed by p3TP-Lux. Similarly, we observed that VACO-9M is not growth inhibited by TGF-b. However, in early studies, transient reconstitution of Smad4 in VACO-9M cells proved insufficient to reconstitute TGF-b cell cycle inhibitory responses (data not shown).
Discussion
In this study, we have characterized a new colon cancer cell line, VACO-9M, that is lacking in Smad4 Thus, the significant function of Smad4 is not the simple carriage of Smad2 and Smad3 into the nucleus, but rather must be at the level of cooperating with Smad2 and Smad3 in transcription factor complexes within the nucleus. It would, however, be premature to conclude that in the absence of Smad4, the nuclear translocations of Smad2 and Smad3 are totally silent events. Rather, we expect that the VACO-9M model will be of value for future studies such as with expression monitoring DNA microarrays that will be able to refine further the spectrum of Smad4-independent responses induced by TGF-b. Such VACO-9M-based studies will be of value as any TGF-b target genes they identify would be defined as a group of TGF-b target genes whose expression is neither linked to growth inhibition nor selected against in cancer.
Materials and methods
Cell culture and reporter assays
The cell lines MDA-MB-468, BxPC3, CFPAC-1, and Hs766T were obtained from the American Type Culture Collection (Manassas, VA, USA). The lines MDA-MB-468 and BxPCS were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, CFPAC-1 was maintained in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine Smad4 independent Smad2 and Smad3 nuclear localization SP Fink et al serum, Hs766T was maintained in DMEM with 4.5 g/l glucose and 10% fetal bovine serum, VACO-9M was maintained in MEM supplemented with 2% fetal bovine serum, insulin, transferrin, selenium, l-glutamine, and hydrocortisone (MEM2+ media) (Willson et al., 1987) , while VACO-400 RII was maintained in MEM2+ supplemented with 300 mg/ml G418.
RT-PCR amplification of Smad2 and Smad4
cDNA was synthesized from 5 mg of total RNA using avian myeloblastosis virus reverse transcriptase (Roche, Indianapolis, IN, USA) and random hexamers. Full-length Smad4 was amplified using the primers 5 0 -TACGCGGATCCAC-CATGGACAATATGTCTATTACGAATAC-3 0 (forward) and 5 0 -TACCGGAATTCCGGATAAACAGGATTGTATT-GTCC-3 0 (reverse). Full-length Smad2 was amplified using the primers 5 0 -GGTAAGAACATGTCGTCCATC-3 0 (forward) and 5 0 -TTTCCATGGGACTTGATTGG-3 0 (reverse). All PCR reactions were carried out in 50 ml volumes using 5 ml of cDNA, and with a final concentration of primer and deoxynucleoside triphosphate of 80 and 125 mm, respectively. 
Western blot
In all, 35 mg of protein was separated by 10% SDS-PAGE and transferred to Immobilont-P PVDF membranes (Millipore, Bedford, MA, USA). Membranes were blocked 1 h at room temperature with 5% nonfat milk, and then incubated overnight at 41C with the appropriate primary antibody. The following day the bolts were washed 3 Â 10 min with PBS/ 0.2% Tween 20, and then incubated with the appropriate secondary antibody coupled to horseradish peroxidase. Enhanced Chemiluminescence Plus and a Storm 840 Phosphoimager (Amersham-Pharmacia, Buckinghamshire, UK) were 
Immunofluorescence staining
Cells were plated 3 days prior to staining, at densities of 30 000 (Hs766T and CFPAC-1), 40 000 (MDA-MB-468 and VACO-9M), 50 000 (VACO-400RII), and 65 000 (BxPC3) cells/ml. The cells were plated in two chamber slides with cover slips (Nalge Nuc International, Naperville, IL, USA) with 1 ml of cell suspension being added to each chamber. The next day, the cells were refed with appropriate media. On the day of staining, 50 m1 of a 0.2 ng/ml stock of TGF-b (R&D Systems, Minneapolis, MN, USA) was then added to appropriate chambers 2 h before the staining of the cells was to begin. After the TGF-b incubation, the cells were washed 3 times for 1 min each with room temperature 1 Â PBS, followed by fixation for 15 min in 1 ml of 4% paraformaldehyde. The cells were then washed 3 times for 1 min each with room temperature 1xPBS, followed by permeabilization with 0.5 ml of 0.1% Triton X-100 for 5 min. After permeabilization, the cells were washed 3 times for 1 min each with room temperature 1 Â PBS, followed by blocking with 10% goat serum for 30 min. The serum was then removed and 450 ml of a 2% goat serum/1 Â PBS solution containing a 1 : 200 dilution of the primary antibody for the respective Smad was added and incubated at room temperature for 1 h. The primary antibodies used were as follows: for Smad4, sc-7966 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); for Smad3, sc-8332 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); and Smad2, S66220 (Transduction Laboratories, Lexington, KY, USA). Cells were then washed 5 times for 1 min in room temperature 1 Â PBS and further incubated with 450 ml of a 2% goat serum/1 Â PBS solution containing a 1 : 400 dilution of a species-specific Alexa-488 labeled secondary antibody (Molecular Probes, Eugene, OR, USA). After incubation, the cells were washed 5 times for 1 min in room temperature 1 Â PBS and then Vectashield s with DAPI (Vector Laboratories, Burlingame, CA, USA) was used as the mounting medium. Images were captured using an E800 Nikon microscope configured with DAPI and FITC fluorescent excitation filters, and equipped with Spot RT s digital camera and Meta Morph s 4.5 software image analysis package (Universal Imaging Corp., West Chester, PA, USA).
